EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Stepping Up to High-Dose Inhaled Corticosteroids in Patients With Asthma: UK Database Study

Ian D Pavord, Trung N Tran, Rupert C Jones, Javier Nuevo, Maarten van den Berge, Guy G Brusselle, Andrew N Menzies-Gow, Derek Skinner, Victoria Carter, Janwillem W H Kocks, David B Price

The Journal of Allergy and Clinical Immunology: In Practice · 2023-02 · 11 (2) · 532-543

DOI: 10.1016/j.jaip.2022.10.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-02. Verfasst von Ian D Pavord und 10 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Oxford, United Kingdom; Nuffield Department of Medicine, University of Oxford, Oxford, Uni…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It is unclear whether patients with asthma benefit from stepping up to high-dose inhaled corticosteroids (ICSs). OBJECTIVE: To determine the effectiveness of stepping up to high-dose ICSs. METHODS: A historic cohort study of patients with asthma (≥13 years old), identified from 2 large UK electronic medical record databases, was conducted. Patients who remained on medium-dose ICSs were compared with those who stepped up from medium- to high-dose ICSs, whereas patients who stepped up from low- to medium-dose ICSs were compared with those who stepped up from low- to high-dose ICSs. Time to first severe exacerbation (primary outcome) between treatment groups was compared using multivariable Cox proportional hazards models, and the number of exacerbations and antibiotics courses was analyzed using negative binomial regression. Inverse probability of treatment weighting was used to handle confounding. RESULTS: The mean follow-up time to first exacerbation was 2.7 ± 2.7 years for those who remained on stable medium-dose ICSs and 2.0 ± 2.2 years for those who stepped up from medium- to high-dose ICSs. A similar pattern was noted for those who stepped up from low- to medium-dose ICSs (2.6 ± 2.5 years) and from low- to high-dose ICSs (2.3 ± 2.5 years). Patients who stepped up from medium- to high-dose ICSs (n = 6879) had a higher risk of exacerbations during follow-up compared with those who remained on medium-dose ICSs (n = 51,737; hazard ratio, 1.17; 95% CI, 1.12-1.22). This was similar in patients stepping up from low- to high-dose (n = 3232) compared with low- to medium-dose (n = 12,659) ICSs (hazard ratio, 1.10; 95% CI, 1.04-1.17). A step-up to high-dose ICSs was also associated with a higher number of asthma exacerbations and antibiotics courses. No significant difference in associations was found across subgroups of patients with different blood eosinophil counts. CONCLUSIONS: We found no evidence that a step-up to high-dose ICSs is effective in preventing future asthma exacerbations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsHumansAdolescentCohort StudiesAdrenal Cortex HormonesProportional Hazards ModelsAdministration, InhalationUnited Kingdom

Stichwörter der Autor:innen

AsthmaCorticosteroidsExacerbationsHigh doseStep-up

Substanzen

Adrenal Cortex HormonesAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Oxford, United Kingdom; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • AstraZeneca, Gaithersburg, Md.
  • Research and Knowledge Exchange, Plymouth Marjon University, Plymouth, United Kingdom.
  • AstraZeneca, Madrid, Spain.
  • Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.

Förderung

  • AstraZeneca

Zitieren

APA

Pavord, I. D., Tran, T. N., Jones, R. C., Nuevo, J., van den Berge, M., Brusselle, G. G., Menzies-Gow, A. N., Skinner, D., Carter, V., Kocks, J. W. H., & Price, D. B. (2023). Effect of Stepping Up to High-Dose Inhaled Corticosteroids in Patients With Asthma: UK Database Study. The Journal of Allergy and Clinical Immunology: In Practice, 11(2), 532-543. https://doi.org/10.1016/j.jaip.2022.10.040

Vancouver

Pavord ID, Tran TN, Jones RC, Nuevo J, van den Berge M, Brusselle GG, et al. Effect of Stepping Up to High-Dose Inhaled Corticosteroids in Patients With Asthma: UK Database Study. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(2):532-543. doi:10.1016/j.jaip.2022.10.040

BibTeX
@article{Pavord2023,
  author = {Pavord, Ian D and Tran, Trung N and Jones, Rupert C and Nuevo, Javier and van den Berge, Maarten and Brusselle, Guy G and Menzies-Gow, Andrew N and Skinner, Derek and Carter, Victoria and Kocks, Janwillem W H and Price, David B},
  title = {Effect of Stepping Up to High-Dose Inhaled Corticosteroids in Patients With Asthma: UK Database Study},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {532--543},
  doi = {10.1016/j.jaip.2022.10.040}
}
Kostenlos starten →